BioStem Technologies, Inc.

https://www.biostemtechnologies.com

BioStem Technologies, Inc. is a regenerative medicine company specializing in the development, manufacture, and commercialization of perinatal tissue allografts. The company's core mission is to produce life-changing products, aiming for excellence in the development and production of such innovations. Headquartered in Pompano Beach, Florida, BioStem Technologies has also secured land for a future headquarters in Boca Raton, Florida.

BioStem Technologies focuses on advanced wound care and regenerative therapies, leveraging its proprietary BioRetain® processing method to preserve the natural properties of perinatal tissue. Its product portfolio includes placental-derived allografts such as VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, AmnioWrap2™, Neox®, and Clarix®. These products are utilized across various market segments, including private offices, ambulatory surgery centers, hospitals, outpatient wound care centers, and federal healthcare systems like the VA and DoD.

Led by CEO and co-founder Jason Matuszewski, BioStem Technologies is actively pursuing growth and market expansion. Recent developments include the appointment of Katherine Gorrell as Chief Legal & Compliance Officer in April 2026 and the acquisition of BioTissue's surgical and wound care business in January 2026. The company is also preparing to release its first-quarter 2026 financial results in May 2026 and is working towards a Nasdaq uplisting to enhance its market presence and liquidity.

Latest updates

BioStem Appoints Experienced Legal Counsel Amid Nasdaq Uplisting Pursuit

Event summary

  • Katherine Gorrell joined BioStem Technologies as Chief Legal & Compliance Officer, effective April 27, 2026.
  • Gorrell previously served as Vice President and General Counsel at Holy Cross Health and held similar roles at AdvancedMD, Intermountain Healthcare, and Providence Health & Services/Swedish Health Services.
  • Her appointment is linked to BioStem’s plans for a Nasdaq uplisting.
  • BioStem is a publicly traded company (OTC: BSEM) focused on regenerative medicine and perinatal tissue allograft products.
  • The company utilizes proprietary technologies like BioRetain®, CryoTek®, and SteriTek®.

The big picture

The appointment of a seasoned legal and compliance executive like Katherine Gorrell signals BioStem’s commitment to strengthening its governance and preparing for a potential Nasdaq listing, a move that would expose the company to greater public scrutiny and institutional investment. This move is typical for smaller, OTC-traded companies seeking to move to a major exchange, but success hinges on demonstrating operational maturity and regulatory compliance. The regenerative medicine sector is facing increased regulatory attention, making a strong compliance foundation essential for long-term viability.

What we're watching

Governance Dynamics
The integration of Medical Affairs under Gorrell’s compliance framework will be a key indicator of BioStem’s operational maturity and ability to handle increased regulatory scrutiny.
Regulatory Headwinds
The company’s progress toward Nasdaq listing will depend heavily on demonstrating robust compliance practices and navigating the evolving regulatory landscape for regenerative medicine products.
Execution Risk
BioStem’s ability to scale operations and maintain its quality management system, as evidenced by AATB accreditation, will be crucial for supporting its growth trajectory and achieving its financial goals.

BioStem Showcases Expanded Portfolio at Key Wound Care Symposium

Event summary

  • BioStem Technologies will present at the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC, from April 8-12, 2026.
  • The company is highlighting its newly introduced Neox product line, expanding its portfolio of perinatal tissue allograft products.
  • A lunch symposium on April 9th will feature Dr. Wendy Weston, William Marston, and Herbert Slade to discuss the expanded portfolio and clinical data.
  • BioStem will present a scientific poster (LR-020) detailing research findings at the conference.

The big picture

BioStem's participation in SAWC underscores the increasing focus on evidence-based regenerative medicine solutions for chronic wound care, a market driven by an aging population and rising prevalence of diabetes. The introduction of the Neox line and expanded portfolio aims to solidify BioStem’s position in a competitive landscape, but success will depend on clinical validation and physician adoption. The company's reliance on allograft tissue positions it within a niche segment of the broader wound care market, which is increasingly subject to regulatory scrutiny and pricing pressures.

What we're watching

Clinical Adoption
The success of the Neox line and expanded portfolio hinges on physician adoption and integration into standard wound care protocols, which will be partially assessed by the symposium feedback.
Data Validation
The randomized controlled trial results on diabetic foot ulcers, presented at the symposium, will be critical in establishing clinical efficacy and securing broader reimbursement.
Competitive Landscape
How BioStem’s expanded product offerings will differentiate against established players in the wound care market and impact pricing strategies remains to be seen.

BioStem to Present at Needham Conference Amidst Tissue Bank Scrutiny

Event summary

  • BioStem Technologies will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 8:45 am ET.
  • The presentation will be webcast live and archived on the company’s investor relations website.
  • BioStem operates within the regenerative medicine sector, specializing in perinatal tissue allograft products.
  • The company’s quality management system is accredited by the American Association of Tissue Banks (AATB) and adheres to cGTP and cGMP standards.

The big picture

BioStem’s presentation at Needham comes at a time when the tissue bank industry is facing increased scrutiny regarding safety and quality control. While the company emphasizes its adherence to cGTP and cGMP standards, maintaining accreditation and navigating potential regulatory changes will be crucial for long-term success. The company’s reliance on proprietary processing technologies and a growing product portfolio suggests a focus on differentiation, but execution risks remain significant in a competitive landscape.

What we're watching

Regulatory Headwinds
Increased regulatory scrutiny of tissue banks, following recent recalls and safety concerns, may impact BioStem’s operational costs and growth trajectory.
Commercial Execution
The success of BioStem’s expanding clinical research initiatives and national commercial footprint will be critical to justifying its current valuation.
Market Dynamics
The adoption rate of BioStem’s allograft solutions across various clinical specialties will determine the company’s ability to capture a larger share of the regenerative medicine market.

BioStem Revenue Plummets Amidst Reimbursement Uncertainty, Nasdaq Uplisting Pursuit

Event summary

  • BioStem Technologies reported Q4 2025 revenue of $10.1 million, a 55% decrease year-over-year.
  • The company acquired BioTissue Holdings Inc. in January 2026, expanding its product portfolio and commercial reach into hospital settings.
  • Full-year 2025 revenue declined to $47.5 million, primarily due to reimbursement uncertainty and increased competition.
  • BioStem expects Q1 2026 revenue to be between $5 million and $6 million, citing marketplace changes and timing issues.

The big picture

BioStem's recent performance highlights the challenges facing regenerative medicine companies navigating complex reimbursement landscapes and increased competition. The BioTissue acquisition represents a strategic pivot towards hospital settings, but the company's revenue decline underscores the fragility of its business model. The Nasdaq uplisting attempt signals ambition, but hinges on demonstrating financial stability and operational improvements.

What we're watching

Reimbursement Risk
The sustainability of BioStem's hospital business hinges on navigating evolving reimbursement policies, which have already significantly impacted physician office revenue.
Integration Execution
The success of the BioTissue acquisition will depend on BioStem’s ability to effectively integrate operations and sales teams, realizing the anticipated synergies.
Nasdaq Requirements
BioStem's pursuit of a Nasdaq uplisting requires audited financial statements, and delays in obtaining these could impact investor confidence and future financing options.

BioStem Adds Seasoned Auditor to Board Amid Expansion Plans

Event summary

  • BioStem Technologies appointed Jodi Ungrodt to its Board of Directors, effective March 18, 2026.
  • Ungrodt will also serve as Chair of the Audit Committee, replacing Brandon Poe who became CFO in August 2025.
  • Ungrodt brings nearly three decades of experience advising life sciences companies at Ernst & Young, including advising on over 30 IPOs.
  • BioStem plans to expand its business beyond chronic wound care and increase its visibility in public markets in 2026.
  • Brandon Poe, former board member, transitioned to the role of Chief Financial Officer.

The big picture

The appointment of Jodi Ungrodt signals BioStem's intent to strengthen its governance and financial controls as it pursues expansion and increased public market presence. This move is typical of smaller, publicly traded MedTech companies seeking to bolster investor confidence and prepare for potential capital raises. The timing aligns with a broader trend of increased regulatory focus and investor demand for robust financial oversight within the regenerative medicine sector.

What we're watching

Governance Dynamics
The Audit Committee's oversight of BioStem's financial reporting will be critical given the company's stated plans for increased public market visibility and expansion, requiring heightened scrutiny.
Regulatory Headwinds
BioStem's adherence to cGTP and cGMP standards, already overseen by the AATB, will face increased pressure as the company expands into acute applications and potentially seeks broader regulatory approvals.
Execution Risk
The success of BioStem’s expansion beyond chronic wound care will depend on its ability to effectively leverage its proprietary technologies and navigate the competitive landscape in new therapeutic areas.

BioStem Schedules Earnings Call Amidst Tissue Allograft Market Scrutiny

Event summary

  • BioStem Technologies will release its Q4 and full-year 2025 financial results on March 24, 2026.
  • The earnings call will feature presentations from CEO Jason Matuszewski and CFO Brandon Poe.
  • The conference call will be held at 4:30 PM ET, accessible via webcast and toll-free/international phone lines.
  • BioStem utilizes the proprietary BioRetain® processing method for its perinatal tissue allograft products.

The big picture

BioStem operates in a niche segment of the regenerative medicine market, focused on perinatal tissue allografts. While the market holds significant long-term potential, it also faces increasing regulatory oversight and competition. The upcoming earnings call will provide insight into BioStem's ability to navigate these challenges and capitalize on the growing demand for regenerative therapies.

What we're watching

Regulatory Headwinds
Increased regulatory scrutiny surrounding tissue processing and allograft safety could impact BioStem's manufacturing costs and product approvals, potentially affecting revenue growth.
Market Dynamics
The competitive landscape within the regenerative medicine market is intensifying, and BioStem’s ability to differentiate its BioRetain® technology and maintain market share will be crucial for sustained profitability.
Execution Risk
The company’s adherence to cGMP and cGT practices, as well as the ongoing accreditation by the AATB, will be vital to maintaining product quality and avoiding costly disruptions to operations.

BioStem to Present at TD Cowen Healthcare Conference Amidst OTC Listing

Event summary

  • BioStem Technologies will present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026, in Boston.
  • The presentation will be accessible via webcast on the company’s investor relations website.
  • BioStem Technologies is an OTC-listed MedTech company focused on perinatal tissue-derived products.
  • The company utilizes a proprietary BioRetain® processing method and holds AATB accreditation for its quality management system.

The big picture

BioStem's presence at TD Cowen’s conference signals an effort to engage with a broader investor base, likely to bolster its OTC listing and raise awareness of its specialized approach to regenerative medicine. The company operates within a niche market focused on perinatal tissue, which presents both opportunities for differentiation and challenges related to sourcing and regulatory compliance. The conference presentation will be a key opportunity to articulate the value proposition of BioRetain® and address investor concerns about the company’s long-term viability.

What we're watching

Listing Status
The company's continued listing on the OTC market will be a key indicator of investor confidence and potential for future capital raises, particularly given the relatively small scale of the MedTech sector.
BioRetain® Adoption
The success of BioStem's proprietary BioRetain® processing method will dictate the company’s ability to differentiate its products and command premium pricing within the competitive regenerative therapies landscape.
Regulatory Scrutiny
Increased regulatory oversight of tissue banks and regenerative therapies, particularly concerning cGTP and cGMP compliance, could impact BioStem’s operational costs and product approval timelines.

BioStem Highlights FDA's Embrace of Bayesian Statistics, Signaling Potential for Accelerated Trials

Event summary

  • BioStem Technologies highlighted FDA Commissioner Makary’s recent endorsement of Bayesian statistical methodologies in clinical trials.
  • The company cites the FDA’s openness to Bayesian approaches as validating its use of advanced statistical analysis in a peer-reviewed study of BioRetain® allografts for diabetic foot ulcers.
  • The study demonstrated BioRetain® achieved superior clinical outcomes, with a nearly two-fold increase in lasting wound closure compared to standard care.
  • BioStem utilizes Bayesian regression and hurdle modeling to quantify probability of wound closure and treatment effect across patient populations.

The big picture

The FDA’s shift towards Bayesian statistical methods represents a potential acceleration of clinical trial processes, particularly beneficial for companies developing therapies with smaller datasets or complex biological mechanisms. BioStem’s proactive adoption of these methods positions it to potentially benefit from this regulatory evolution, but also increases scrutiny on the rigor of its data analysis. This move could also encourage other MedTech companies to adopt Bayesian approaches, potentially increasing competition in the advanced wound care market.

What we're watching

Regulatory Headwinds
The FDA’s formal guidance on Bayesian methods, and its impact on BioStem’s trial design and approval timelines, warrants close monitoring. Wider adoption of Bayesian approaches could accelerate approval pathways for similar therapies.
Execution Risk
BioStem’s ability to consistently apply these advanced statistical techniques across its ongoing and future clinical trials will be crucial to maintaining credibility and attracting investment.
Market Adoption
The extent to which physicians and health systems integrate BioRetain® and similar products into standard wound care protocols will determine the long-term commercial success of BioStem’s technology.

BioStem Acquires BioTissue Wound Care Business to Expand Acute Care Footprint

Event summary

  • BioStem Technologies acquired BioTissue Holdings’ surgical and wound care business for approximately $15 million upfront, with up to $25 million in potential milestone payments.
  • The acquired business generated $29 million in sales in 2025 and is expected to contribute positive EBITDA to BioStem in 2026.
  • BioStem has promoted Barry Hassett to Chief Commercial Officer, leveraging his prior experience with BioTissue.
  • The acquisition includes BioTissue’s Neox® and Clarix® product lines and access to major GPO networks.

The big picture

BioStem’s acquisition of BioTissue’s surgical and wound care business represents a strategic shift towards expanding its presence in the acute wound care market, a segment with significant growth potential but also demanding regulatory scrutiny and competitive pressures. The $29 million revenue base acquired provides a foundation for growth, but the company must now demonstrate its ability to leverage the acquired assets and commercial infrastructure to achieve its stated goals. This move signals a broader trend of MedTech companies seeking to consolidate fragmented markets through acquisition.

What we're watching

Integration Risk
The success of the acquisition hinges on BioStem’s ability to effectively integrate BioTissue’s commercial infrastructure and product lines, a process that can be operationally complex and potentially disruptive.
Milestone Payments
The potential $25 million in milestone payments tied to 510(k) clearance and commercial royalties represent a significant contingent liability and will depend on BioStem’s regulatory and market execution.
Acute Care Adoption
The ability of BioStem’s acquired products to gain traction and market share within the acute wound care segment will be critical to justifying the acquisition price and achieving projected revenue growth.

CMS Withdraws Skin Substitute Reimbursement Rules, Benefiting BioStem

Event summary

  • CMS withdrew all seven Local Coverage Determinations (LCDs) for skin substitute grafts, effective January 1, 2026.
  • The LCDs pertained to treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU).
  • BioStem Technologies CEO Jason Matuszewski stated the withdrawal won't impact patient access to BioStem’s VENDAJE® and VENDAJE AC® products.
  • BioStem intends to continue investing in clinical data to demonstrate the performance of its technology.

The big picture

The CMS’s decision to withdraw these LCDs represents a temporary reprieve for BioStem and other skin substitute manufacturers facing reimbursement pressures. This move suggests a broader reassessment of coverage policies for advanced wound care therapies, potentially reflecting a desire to balance innovation with fiscal responsibility. However, the long-term reimbursement landscape remains uncertain, and BioStem's success hinges on its ability to demonstrate clinical value and navigate evolving regulatory frameworks.

What we're watching

Reimbursement Risk
While the current withdrawal is positive, future CMS policy shifts remain a significant risk to BioStem's revenue model, requiring ongoing engagement with policymakers.
Clinical Validation
BioStem’s commitment to evidence-based strategy will be critical; the company must consistently generate and publish data demonstrating superior clinical outcomes to justify pricing and maintain market position.
Competitive Landscape
The absence of restrictive LCDs may encourage increased competition within the skin substitute market, potentially impacting BioStem’s pricing power and market share.

BioStem’s Skin Substitute Reimbursement Faces 12-Month Review

Event summary

  • BioStem Technologies’ VENDAJE® and VENDAJE AC® products have been placed on a 12-month “Status Quo” list by CMS for reimbursement related to diabetic foot ulcers (DFU) and venous leg ulcers (VLU).
  • The “Status Quo” designation maintains reimbursement eligibility for 2026, requiring adherence to the “reasonable and necessary” standard.
  • Coverage for pressure ulcers, representing 41% of the chronic wound market and the majority of BioStem’s revenue, remains unaffected.
  • CMS will reconsider the LCD in early 2027 after reviewing evidence submitted by December 31, 2026.

The big picture

This CMS action highlights the ongoing volatility in Medicare reimbursement for advanced wound care products, a sector increasingly subject to rigorous scrutiny. While the “Status Quo” designation provides temporary relief, it underscores the need for BioStem to proactively engage with regulators and build a robust evidence base to ensure long-term market access. The company's reliance on pressure ulcer treatment for the majority of its revenue also exposes it to potential shifts in reimbursement policy for that indication.

What we're watching

Reimbursement Risk
The 12-month status quo period introduces significant reimbursement risk, as MACs will scrutinize claims and CMS will reassess coverage based on new evidence.
Clinical Data
BioStem’s ability to generate and present compelling clinical data, particularly regarding DFU superiority, will be critical to securing a move from “Status Quo” to “Covered” status.
Market Dynamics
The continued stability of BioStem’s pressure ulcer revenue stream will be key, as any shift in reimbursement for this segment could significantly impact overall financial performance.
CID: 518